{"title":"Centrifugation-based plasma exchange overcomes blood flow restriction to rescue hyperviscosity syndrome in IgM-κ multiple myeloma: a case report.","authors":"Hiroto Osakabe, Shinkuro Yamamoto, Ryu Shigehisa, Yuki Osakabe, Tatsuki Matsumoto, Rie Yoshimura, Satoshi Fukata, Keiji Inoue","doi":"10.1007/s10047-026-01578-3","DOIUrl":null,"url":null,"abstract":"<p><p>When blood flow cannot be raised to the 150-200 mL/min threshold required for membrane-based therapeutic plasma exchange, centrifugation-based therapeutic plasma exchange represents the only mechanistically viable option-yet this specific clinical scenario has not been reported. We describe an 86-year-old man with IgM-κ multiple myeloma who developed hyperviscosity syndrome. Sequential membrane-based approaches failed owing to blood flow restriction: double-filtration plasmapheresis was discontinued when secondary membrane pressure reached 277 mmHg, and membrane-based therapeutic plasma exchange achieved only a 20.1% IgM level reduction at a subtherapeutic flow of 45-60 mL/min. Centrifugation-based therapeutic plasma exchange, operable at 10-150 mL/min, was performed in two sessions via bilateral peripheral antecubital venous access using fresh frozen plasma, achieving IgM level reductions of 67.3 and 66.2% with prompt symptomatic relief and no serious adverse events. Diagnosis of IgM-κ multiple myeloma was established by absence of the MyD88 L265P mutation and presence of t(11;14) on bone marrow cytogenetics. The patient was discharged on lenalidomide plus dexamethasone, with no hyperviscosity syndrome recurrence at follow-up. To our knowledge, this is the first reported case in which centrifugation-based therapeutic plasma exchange served as rescue therapy in a patient for whom blood flow restriction rendered membrane-based modalities non-functional-a clinical niche not addressed in prior comparative studies.</p>","PeriodicalId":15177,"journal":{"name":"Journal of Artificial Organs","volume":"29 3","pages":""},"PeriodicalIF":1.2000,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Artificial Organs","FirstCategoryId":"5","ListUrlMain":"https://doi.org/10.1007/s10047-026-01578-3","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"ENGINEERING, BIOMEDICAL","Score":null,"Total":0}
引用次数: 0
Abstract
When blood flow cannot be raised to the 150-200 mL/min threshold required for membrane-based therapeutic plasma exchange, centrifugation-based therapeutic plasma exchange represents the only mechanistically viable option-yet this specific clinical scenario has not been reported. We describe an 86-year-old man with IgM-κ multiple myeloma who developed hyperviscosity syndrome. Sequential membrane-based approaches failed owing to blood flow restriction: double-filtration plasmapheresis was discontinued when secondary membrane pressure reached 277 mmHg, and membrane-based therapeutic plasma exchange achieved only a 20.1% IgM level reduction at a subtherapeutic flow of 45-60 mL/min. Centrifugation-based therapeutic plasma exchange, operable at 10-150 mL/min, was performed in two sessions via bilateral peripheral antecubital venous access using fresh frozen plasma, achieving IgM level reductions of 67.3 and 66.2% with prompt symptomatic relief and no serious adverse events. Diagnosis of IgM-κ multiple myeloma was established by absence of the MyD88 L265P mutation and presence of t(11;14) on bone marrow cytogenetics. The patient was discharged on lenalidomide plus dexamethasone, with no hyperviscosity syndrome recurrence at follow-up. To our knowledge, this is the first reported case in which centrifugation-based therapeutic plasma exchange served as rescue therapy in a patient for whom blood flow restriction rendered membrane-based modalities non-functional-a clinical niche not addressed in prior comparative studies.
期刊介绍:
The aim of the Journal of Artificial Organs is to introduce to colleagues worldwide a broad spectrum of important new achievements in the field of artificial organs, ranging from fundamental research to clinical applications. The scope of the Journal of Artificial Organs encompasses but is not restricted to blood purification, cardiovascular intervention, biomaterials, and artificial metabolic organs. Additionally, the journal will cover technical and industrial innovations. Membership in the Japanese Society for Artificial Organs is not a prerequisite for submission.